Part 2. Imatinib for Gastrointestinal Stromal Tumors (GISTs) (continued)

References

1. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. British Journal of Surgery Oct 2003;90(10):1178-1186.

2. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of Surgery Jan 2000;231(1):51-58.

3. Demetri GD, DeMatteo RP. NCCN Gastrointestinal Stromal Tumors (GIST) Task Force Report: National Comprehensive Cancer Network; 2004.

4. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Current Treatment Options in Oncology Dec 2001;2(6):485-491.

5. Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Annals of Surgical Oncology Jan 1995;2(1):26-31.

6. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study [see comment]. Lancet Oct 27 2001;358(9291):1421-1423.

7. Langer C, Gunawan B, Schuler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. British Journal of Surgery Mar 2003;90(3):332-339.

8. Lin SC, Huang MJ, Zeng CY, et al. Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. World Journal of Gastroenterology Dec 2003;9(12):2809-2812.

9. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. Journal of Clinical Pathology Feb 2001;54(2):96-102.

10. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathology Oct 1999;30(10):1213-1220.

11. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Modern Pathology Aug 1998;11(8):728-734.

12. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Research Sep 1 1999;59(17):4297-4300.

13. Lee JH, Zhang X, Jung WY, et al. DNA ploidy and c-Kit mutation in gastrointestinal stromal tumors. World Journal of Gastroenterology Dec 1 2004;10(23):3475-3479.

14. Yamaguchi M, Tate G, Endo Y, et al. Immunohistochemistry and c-kit gene analysis in determining malignancy in gastrointestinal stromal tumors. Hepato-Gastroenterology Sep-Oct 2003;50(53):1431-1435.

15. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. American Journal of Surgical Pathology Jan 2005;29(1):52-68.

16. Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastro-intestinal stromal tumours—a systematic review and economic evaluation. Birmingham, UK: National Institute for Clinical Excellence; October 10, 2003.

17. Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Laboratory Investigation Dec 1998;78(12):1633-1636.

18. Yasuoka R, Sakakura C, Shimomura K, et al. Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation as a prognostic biomarker for gastrointestinal mesenchymal tumor. Digestive Surgery 2003;20(3):183-191.

19. Morey AL, Wanigesekera GD, Hawkins NJ, et al. C-kit mutations in gastrointestinal stromal tumours. Pathology Aug 2002;34(4):315-319.

20. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical Cancer Research Aug 15 2003;9(9):3329-3337.

21. Lasota J, Kopczynski J, Sarlomo-Rikala M, et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Human Pathology Dec 2003;34(12):1306-1312.

22. Yamamoto H, Oda Y, Kawaguchi K, et al. c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue). American Journal of Surgical Pathology Apr 2004;28(4):479-488.

23. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology Sep 2003;125(3):660-667.

24. Miettinen M, El-Rifai W, Sobin, LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathology May 2002;33(5):478-483.

25. Fletcher CDM, Berman JJ, Corless C, , et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathology 2002;33(5):459-465.

26. Tryggvason G, Gíslason HG, Magnusson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. International Journal of Cancer 2005;117:289-293.

27. Heinrich MC, Shoemaker JS, Corless CL, et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). 2005 ASCO Annual Meetings, 2005: Abstract #7.

28. Anonymous. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet Dec 6 1997;350(9092):1647-1654.

29. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65(Suppl 2):80-84.

30. Adult Soft Tissue Sarcoma (PDQ®): Treatment:  Recurrent Adult Soft Tissue Sarcoma. 2/1/05; http://cancer.gov/cancertopics/pdq/treatment/adult-soft-tissue-sarcoma/HealthProfessional/page8#Reference8.12. Accessed March 27, 2005.

31. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematology-Oncology Clinics of North America Aug 1995;9(4):765-785.

32. Bramwell V, Anderson D, Charette M. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Practice Guideline Report #11-1. July 2004; http://www.cancercare.on.ca/pdf/pebc11-1f.pdf. Accessed March 27, 2005.

33. Biermann JS, Baker LH. The future of sarcoma treatment. Seminars in Oncology Oct 1997;24(5):592-597.

34. Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. Journal of Clinical Oncology Jan 1989;7(1):126-131.

35. van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. European Journal of Cancer Dec 2002;38(18):2397-2406.

36. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies―dose-response and schedule dependence. Journal of Clinical Oncology Jun 1997;15(6):2378-2384.

37. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Journal of Clinical Oncology Jul 1993;11(7):1276-1285.

38. Blanke CD, Corless CL. State-of-the Art Therapy for Gastrointestinal Stromal Tumors. Cancer Investigation 2005;23(3):278-280.

39. von Mehren MWJC. Gastrointestinal stromal tumors. Hematology-Oncology Clinics of North America 2005;19(3):547-564, vii.

40. Eisenberg BL. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology (Huntington) 1626 passim, 2003 Nov 1623;17(11):1615-1620; discussion 1620.

41. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. Journal of Clinical Oncology 2005;23(23):5357-5364.

42. Gleevec® and GIST. 2005; http://www.gleevec.com/info/page/gist. Accessed March 27, 2005.

43. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clinical Cancer Research Oct 2002;8(10):3034-3038.

44. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine 2002;347(7):472-480.

45. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer Sep 2002;38 Suppl 5:S83-87.

46. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [see comment]. New England Journal of Medicine Aug 15 2002;347(7):472-480.

47. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology Dec 1 2003;21(23):4342-4349.

48. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study [see comment]. European Journal of Cancer Sep 2003;39(14):2006-2011.

49. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial [see comment]. Lancet Sep 25 2004;364(9440):1127-1134.

50. Zalcberg J, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD)―an international, intergroup study of the EORTC, ISG and AGITG. Journal of Clinical Oncology 2004;22(14S):9004.

51. Casali P, Fumagalli E, Messina A, et al. Tumor response to imatinib mesylate in advanced GIST. Journal of Clinical Oncology 2004;22(14S):9028.

52. Blay J-Y, Berthaud P, Perol D, et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. Journal of Clinical Oncology 2004;22(14S):9006.

53. Rankin C, von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST—Phase III Sarcoma Group Study S0033. Journal of Clinical Oncology 2004;22(14S):9005.

54. Patel SR. Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors. Current Oncology Reports Jul 2003;5(4):273.

55. Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. British Journal of Cancer Aug 4 2003;89(3):460-464.

56. Rutkowski P, Nyckowski P, Grzesiakowska U, et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). Neoplasma 2003;50(6):438-442.

57. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? American Journal of Surgery Dec 2003;186(6):665-669.

58. Wu PC, Langerman A, Ryan CW, et al. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery Oct 2003;134(4):656-665; discussion 665-656.

59. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer Mar 2004;40(5):689-695.

60. Frolov A, Chahwan S, Ochs M, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Molecular Cancer Therapeutics Aug 2003;2(8):699-709.

61. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) [see comment]. European Journal of Cancer Sep 2003;39(14):2012-2020.

62. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. Journal of Nuclear Medicine Mar 2004;45(3):357-365.

63. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors [erratum appears in J Nucl Med 2004 Nov;45(11):1803]. Journal of Nuclear Medicine Jan 2004;45(1):17-21.

64. De Giorgi U, Aliberti G, Benea G, et al. Effect of angio-echography with a second-generation contrast agent to assess tumor response to imatinib treatment in patients with advanced gastrointestinal stromal tumor (GIST): Comparison with computerized tomography (CT). Journal of Clinical Oncology 2004;22(14S):4216.

65. Lassau N, Lamuraglia M, Leclere J, et al. Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: Results of a prospective study. Journal of Clinical Oncology 2004;22(14S):9048.

66. Hellies R, Sulis R, Puliga A, et al. [GIST: surgical treatment of 34 cases]. Tumori Jul-Aug 2003;89(4 Suppl):133-134.

67. Michael M, Tannock IF. Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. Canadian Medical Association Journal 1998;158(13):1727-1734.

68. Dematteo RD, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Human Pathology 2002;33(5):466-477.

69. Demetri G, von Mehren, M, Joensuu, H,  et al. Lack of progress is the most significant measure of patients's lack of clinical benefit: correlating the effects of imatinib meslyate therapy in gastrointestinal stromal tumor (GIST) with survival benefits. Annals of Oncology 2004;15(s3):iii202.

70. ClinPharm Online. http://cpip.gsm.com, 2005.

71. Verweij J, Casali PB, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.

72. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD)—an international, intergroup study of the EORTC, ISG and AGITG. Journal of Clinical Oncology 2004;22(14):9004.

73. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST—Phase III Sarcoma Group Study S0033. Journal of Clinical Oncology. 2004;22(14):9005.

74. D'Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12(1):44-56.

75. Milandri C, Passardi A, Dall'agata M, et al. Gastrointestinal stromal tumors and breast cancer: any correlation? Report of two clinical cases. Journal of Clinical Oncology 2005;23(16S):abstract #9049.

76. Linton KM, Taylor MB, Radford JA. Response evaluation in GIST treated with imatinib-misdiagnosis of disease progression on CT due to cystic change in liver metastases. Journal of Clinical Oncology 2005;23(16S):abstract #9047.

77. Khan A. Efficacy of imatinib mesylate in metastatic GIST to the brain. Journal of Clinical Oncology 2005;23(16S):abstract #9050.

78. Leong KW, Goh SA. Observation study on Asian patients taking Imatinib mesylate in comparison to published data focusing on dosage and adverse events. Journal of Clinical Oncology 2005;23(16S):abstract #6727.

79. Gronchi A, Fiore M, Bertulli R, et al. Surgery of residual disease following Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology 2005;23(16S):abstract #9038.

80. Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy. Journal of Clinical Oncology 2005;23(16S):abstract 9037.

81. Trent JC, Choi H, Hunt K, et al. Apoptotic and anti-vascular activity of imatinib in GIST patients. Journal of Clinical Oncology 2005;23(16S):abstract #9001.

82. Lassau N, Lamuraglia M, Chami L, et al. Doppler-Ultrasonography with perfusion software and contrast medium injection as a tool for early evaluation of gastro-intestinal stromal tumors (GIST) treated with Imatinib. Journal of Clinical Oncology 2005;23(16S):abstract #3057.

83. Blackstein Me, Rankin CJ, Fletcher C, et al. Clinical benefit of Imatinib in patients (pts) with metastatic Gastrointestinal Stromal Tumors (GIST) negative for the expression of CD117 in the S0033 trial. Journal of Clinical Oncology 2005;23(16S):abstract #9010.

84. Dileo P, Rankin CJ, Bejamin RS, et al. Incidence and reasons for dose modification of standard-dose vs. high-dose Imatinib Mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic Gastrointestinal Stromal Tumor (GIST). Journal of Clinical Oncology 2005;23(16S):abstract #9032.

85. Heinrich M, Shoemaker JS, Corless CL, et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). Journal of Clinical Oncology 2005;23(16S):abstract #7.

86. Ray-Coquard I, Perol D, Bui BN, et al. Prognostic factors for progression free and overall survival in advanced GIST: results from the BFR14 phase III trial of the French Sarcoma Group. Journal of Clinical Oncology 2005;23(16S):abstract #9035.

87. Le Cesne A, Perol D, Ray-Coquard I, et al. Interruption of imatinib (IM) in GIST patients with advanced disease: updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. Journal of Clinical Oncology 2005;23(16S):abstract #9031.

88. Dematteo RP, Antonescu CR, Chadaram V, et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. Journal of Clinical Oncology 2005;23(16S):Abstract #9009.

89. Bustamante F, Castillo E, Silva A, et al. Experiences with gastrointestinal stromal tumour at the Oncology Hospital Siglo XXI IMSS. Journal of Clinical Oncology 2005;23(16S):abstract #9048.

90. Stepanova E, Meshcheryakov A, Anurova O, et al. Immunohistochemical markers as prognostic indicators for efficacy of imatinib therapy in GIST. Journal of Clinical Oncology 2005;23(16S):abstract #9703.

91. Ryu M, Lee H, Kim T, et al. p53 mutation as a determinant of prognosis in GIST patients treated with Imatinib mesylate. Journal of Clinical Oncology 2005;23(16S):abstract #9018.

92. Kim J, Lim M, Kim I, et al. Prognostic analysis of gastrointestinal stromal tumor by mitotic activity, size of tumor and mutational type of C-Kit protein. Journal of Clinical Oncology 2005;23(16S):abstract #9046.

93. Aliberti S, Grignani G, Allione P, et al. Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained finding in GIST imatinib (I) chronic therapy. Journal of Clinical Oncology 2005;23(16S):abstract #9045.

94. Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. A population-based study in Western Sweden. Cancer 2005;103(4)821-9.

Return to Contents
Proceed to Next Section